CN Patent

CN104640547B — 具有改善的溶出度和/或吸收的用于口服的药物组合物

Assigned to Taiho Pharmaceutical Co Ltd · Expires 2017-07-11 · 9y expired

What this patent protects

用于口服的药物组合物包含作为活性药物成分的4‑((1‑甲基吡咯‑2‑基)‑羰基)‑N‑(4‑(4‑吗啉‑1‑基‑羰基哌啶‑1‑基)‑苯基)‑1‑哌嗪甲酰胺或其盐或其溶剂化物，并且包含作为酸添加剂的己二酸、琥珀酸、富马酸、L‑天冬氨酸、L‑谷氨酸、或其任意组合。

USPTO Abstract

用于口服的药物组合物包含作为活性药物成分的4‑((1‑甲基吡咯‑2‑基)‑羰基)‑N‑(4‑(4‑吗啉‑1‑基‑羰基哌啶‑1‑基)‑苯基)‑1‑哌嗪甲酰胺或其盐或其溶剂化物，并且包含作为酸添加剂的己二酸、琥珀酸、富马酸、L‑天冬氨酸、L‑谷氨酸、或其任意组合。

Drugs covered by this patent

Patent Metadata

Patent number
CN104640547B
Jurisdiction
CN
Classification
—
Expires
2017-07-11
Drug substance claim
No
Drug product claim
No
Assignee
Taiho Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.